Drugs / Onvansertib
Onvansertib
also known as
NMS-1286937 · NMS-P937 · Nms-p937 fumarate · Nms-p937 fumarate salt · ONVANSERTIB FUMARATE · PCM-075 · Pcm-075 fumarate · PMS-075H
Small molecule targets PLK1 via inhibition
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04005690 | Aug 2019 → Jun 2026 overdue | pancreatic ductal adenocarcinoma | OHSU Knight Cancer Institute | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05549661 | Apr 2023 → Jun 2027 expected | atypical chronic myeloid leukemia, BCR-ABL1 negative, chronic myelomonocytic leukemia | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT01014429 | Nov 2009 → Oct 2011 | — | Nerviano Medical Sciences | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06736717 | Feb 2025 → Jul 2026 overdue | malignant pancreatic neoplasm | University of Kansas Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05383196 | Sep 2022 → Dec 2026 expected | inflammatory breast carcinoma, triple-negative breast carcinoma | Antonio Giordano, MD | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03829410 | Jun 2019 → Jan 2024 | colorectal cancer | Cardiff Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT03303339 | Nov 2017 → Nov 2021 | acute myeloid leukemia | Cardiff Oncology | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT06398587 | Aug 2024 → May 2026 | pancreatic ductal adenocarcinoma | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT06106308 | Feb 2024 → Nov 2026 expected | colorectal cancer | Cardiff Oncology | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05593328 | Mar 2023 → Dec 2024 | colorectal cancer | Cardiff Oncology | Completed | No outcome recorded |
| Phase 2 | NCT05450965 | Jul 2022 → Aug 2027 expected | small cell lung carcinoma | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 2 | NCT04752696 | May 2021 → Dec 2024 | pancreatic ductal adenocarcinoma | Cardiff Oncology | Completed | No outcome recorded |
| Phase 2 | NCT03414034 | Aug 2018 → Oct 2023 | prostate carcinoma | Cardiff Oncology | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04446793 | — | colorectal cancer | Cardiff Oncology | No longer available | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Onvansertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05549661 ↗ |
| Known as | NMS-1286937 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01014429 ↗ |
| Known as | NMS-P937 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738758 ↗ |
| Known as | Nms-p937 fumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738758 ↗ |
| Known as | Nms-p937 fumarate salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738758 ↗ |
| Known as | ONVANSERTIB FUMARATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738758 ↗ |
| Known as | PCM-075 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738758 ↗ |
| Known as | Pcm-075 fumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738758 ↗ |
| Known as | PMS-075H | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738758 ↗ |
| Action | Inhibit | “polo-like-kinase 1 inhibitor” NCT01014429 ↗ |
| Modality | Small molecule | “Onvansertib is a small chemical molecule” NCT06398587 ↗ |
| Route | Oral | “Onvansertib orally” NCT03303339 ↗ |
| Target | PLK1 | “polo-like-kinase 1 inhibitor” NCT01014429 ↗ |